^
Association details:
Biomarker:BRAF V600K
Cancer:Cutaneous Melanoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Published date:
03/31/2020
Excerpt:
Recommendation 2.3….For patients with resected stage IIIA/B/C/D BRAF-mutant (V600E/K*) disease, the following therapy options should be offered (in no particular order)…pembrolizumab…52 weeks...
DOI:
10.1200/JCO.20.00198